הנה ציטוט התקציר של מאמר מכתב עת עולמי על בעיות גסטרואנטרולוגיות. כותב המאמר סקר את כל המחקרים על סינדרום המעי הרגיז שפורסמו בכתבי העת הרפואיים משנת 2008 ועד 2014, כדי לבדוק מהם החידושים לגבי הידע והטיפול בסינדרום. קוראי אנגלית יוכלו לקרוא את הציטוט שבהמשך. לצערנו, הסיכום הוא שעדיין אין שום תרופה ידועה או טיפול מומלץ לריפוי, עוד יותר עצוב לדעת שכמו הסוכרת, אין ריפוי למחלה והסינדרום מלווה את האדם במשך כל חייו. אז אם יש למישהו רעינות להקלה - מוזמן להציע. אני מצאתי מספר דרכים להקלה ואמסור בהמשך. רבקה World J Gastroenterol. 2014 Jul 21; 20(27): 8867–8885. Published online 2014 Jul 21. doi:  10.3748/wjg.v20.i27.8867PMCID: PMC4112893 Recent advances in pharmacological treatment of irritable bowel syndromeGeorgia Lazaraki, Grigoris Chatzimavroudis, and Panagiotis KatsinelosGeorgia Lazaraki, Grigoris Chatzimavroudis, Panagiotis Katsinelos, Department of Endoscopy and Motility Unit, G. Gennimatas General Hospital, School of Medicine, Aristotle University of Thessaloniki, 54635 Thessaloniki, Greece Author contributions: Lazaraki G mainly drafted and wrote the manuscript; Chatzimavroudis G is involved in writing and editing the manuscript; Katsinelos P is responsible for drafting and critical approval of the manuscript. Correspondence to: Panagiotis Katsinelos, MD, PhD, Assistant Professor of Gastroenterology, Department of Endoscopy and Motility Unit, G. Gennimatas General Hospital, School of Medicine, Aristotle University of Thessaloniki, Ethnikis Aminis 41, 54635 Thessaloniki, Greece. rg.oohay@vamiztahcgTelephone: +30-2310-963341+30-2310-963341 Fax: +30-2310-963341+30-2310-963341Author information ► Article notes ► Copyright and License information ►Received 2013 Oct 1; Revised 2014 Mar 13; Accepted 2014 Jun 20.Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved. This article has been cited by other articles in PMC.Go to:Abstract Irritable bowel syndrome (IBS) is a highly prevalent functional disorder that reduces patients’ quality of life. It is a chronic disorder characterized by abdominal pain or discomfort associated with disordered defecation in the absence of identifiable structural or biochemical abnormalities. IBS imposes a significant economic burden to the healthcare system. Alteration in neurohumoral mechanisms and psychological factors, bacterial overgrowth, genetic factors, gut motility, visceral hypersensitivity, and immune system factors are currently believed to influence the pathogenesis of IBS. It is possible that there is an interaction of one or more of these etiologic factors leading to heterogeneous symptoms of IBS. IBS treatment is predicated upon the patient’s most bothersome symptoms. Despite the wide range of medications and the high prevalence of the disease, to date no completely effective remedy is available. This article reviews the literature from January 2008 to July 2013 on the subject of IBS peripherally acting pharmacological treatment. Drugs are categorized according to their administration for IBS-C, IBS-D or abdominal pain predominant IBS. Keywords: Irritable bowel syndrome, Irritable bowel syndrome constipation, Irritable bowel syndrome-diarrhea, Constipation, Diarrhea, Irritable bowel syndrome treatment, Irritable bowel syndrome-pain Core tip: Irritable bowel syndrome (IBS) is a highly prevalent functional disorder that reduces patients’ quality of life and imposes a significant economic burden to the healthcare system. This article extensively reviews the literature from January 2008 to July 2013 on the subject of IBS peripherally acting pharmacological treatment. Pathophysiology background and mode of action in IBS of each substance are also discussed.